#News for #Investors and #Media:
At #TLM26 we’re unveiling our latest advancements across our hepatology pipeline for chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and alcohol-related liver disease (ALD).
🔗 Find out more: gsk.to/3Uct1hi
#News for #Investors and #Media: At #TLM26 we’re unveiling our latest advancements across our hepatology pipeline for chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and alcohol-related liver disease (ALD). 🔗 Find out more: gsk.to/3Uct1hi
0 vue
Publié le 05/11/2026 15:04
0:07
#News for #Investors and #Media:
At #TLM26 we’re unveiling our latest advancements across our hepatology pipeline for chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and alcohol-related liver disease (ALD).
🔗 Find out more: gsk.to/3Uct1hi
0 commentaire
?